Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
15
2023-03
Boan Biotech Announces Publication of Phase 1 Clinical Study Results of BA5101 in the Journal of Expert Opinion on Biological Therapy
14
2023-03
Patient Enrollment Completed for BA9101 Phase 3 Clinical Study
16
2023-02
Boan’s BA2101 Administered for First Patient in Clinical Trial
13
2023-02
Boan’s BA1106 Administered for First Patient in Clinical Trial
13
2023-01
Boan Biotech Publishes Research Results of Self-Developed Neutralizing Antibody Against SARS-CoV-2 Variants in Nature Sub-Journal
03
2023-02
Boan Biotech Partners with CP Qingdao to Accelerate the Commercialization of Boyoubei® in China
09
2023-01
Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China
30
2022-12
Boan Biotech Officially Listed on the Main Board of SEHK Accelerating to Become a Leading Global Biopharmaceutical Company
11
2022-11
China’s First Denosumab Biosimilar Boyoubei® Approved for Launch by NMPA
28
2022-10
Boan Biotech’s BA2101 Injection Approved for Clinical Trials in China
3
4
5
6
7
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
